Results 91 to 100 of about 80,266 (330)

A Facile Protocol for C(sp2)–C(sp3) Bond Formation Reactions Toward Functionalized E3 Ligase Ligands

open access: yesChemMedChem, EarlyView.
A robust C(sp2)–C(sp3) decarboxylative coupling strategy enables access to new CRBN ligands and degraders with improved physicochemical properties. This synthetic approach is expanding the chemical space beyond C(sp2)–N linkages, fine‐tuning proteolysis‐targeting chimera activities and unlocking previously inaccessible degrader chemotypes.
Anita Maksutova   +15 more
wiley   +1 more source

Anatomy of point-contact Andreev reflection spectroscopy from the experimental point of view (review) [PDF]

open access: yes, 2018
We review application of point-contact Andreev-reflection spectroscopy to study elemental superconductors, where theoretical conditions for the smallness of the point-contact size with respect to the characteristic lengths in the superconductor can be ...
Andreev A. F.   +26 more
core   +2 more sources

BTK: sensing pathogenic nucleic acids

open access: yesOncotarget, 2015
We are under constant threats from pathogens. A failure to initiate an appropriate immune response will lead to an immunocompromised state. Our innate immune system could sense foreign nucleic acids from parasites, viruses, fungi and bacteria. This is achieved through pattern recognition receptors (PRRs) on innate cells such as macrophages that ...
Koon-Guan, Lee, Kong-Peng, Lam
openaire   +2 more sources

Integrin Signaling Shaping BTK-Inhibitor Resistance

open access: yesCells, 2022
Integrins are adhesion molecules that function as anchors in retaining tumor cells in supportive tissues and facilitating metastasis. Beta1 integrins are known to contribute to cell adhesion-mediated drug resistance in cancer. Very late antigen-4 (VLA-4), a CD49d/CD29 heterodimer, is a beta1 integrin implicated in therapy resistance in both solid ...
Laura Polcik   +5 more
openaire   +4 more sources

How we use Genomics and BTK-Inhibitors in the Treatment of Waldenstrom Macroglobulinemia.

open access: yesBlood
Mutations in MYD88 (95-97%) and CXCR4 (30-40%) are common in Waldenstrom macroglobulinemia (WM). TP53 is also altered in 20-30% of WM patients, particularly those previously treated.
S. Treon, S. Sarosiek, J. Castillo
semanticscholar   +1 more source

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition

open access: yesBlood Advances, 2021
Key Points Patients with CLL sequentially resistant to both BCL2 and covalent BTK inhibition have a poor prognosis and represent an area of unmet need.
T. Lew   +12 more
semanticscholar   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

open access: yesEnvironmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons   +17 more
wiley   +1 more source

Előszó

open access: yesElpis, 2020
Jelen számunkat Steiger Kornél 75. születésnapja alkalmából állítottuk össze. Az ünnepeltet Mogyoródi Emese később a mi nevünkben is köszönti, ezért itt a szerkesztési elveket emelnénk ki.
Nikoletta Hendrik, Kosztasz Rosta
doaj  

Clinical feasibility of endovascular recanalization with intravascular ultrasound-guided wiring for chronic total occlusion of below-the-knee arteries

open access: yesCVIR Endovascular, 2023
Background Revascularization with endovascular therapy (EVT) for complex below-the-knee (BTK) chronic total occlusion (CTO) remains a challenging problem.
Naoki Hayakawa   +7 more
doaj   +1 more source

Mártonfi Ferenc halálának 30. évfordulójára

open access: yesTávol-keleti Tanulmányok, 2022
Bartos Huba emlékezése Mártonfi Ferencre.
Huba Bartos
doaj   +1 more source

Home - About - Disclaimer - Privacy